Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats

• Published in: Journal of neuroscience research 2003-04, Vol.72 (2), p.268-278
• Main Authors: Milicevic, Irena, Pekovic, Sanja, Subasic, Sanja, Mostarica-Stojkovic, Marija, Stosic-Grujicic, Stanislava, Medic-Mijacevic, Ljubica, Pejanovic, Vjera, Rakic, Ljubisav, Stojiljkovic, Mirjana
• Format: Article
• Language: English
• Subjects: Adjuvants, Immunologic - pharmacology; Animals; Demyelinating Diseases - drug therapy; Demyelinating Diseases - prevention & control; Disease Models, Animal; Disease Susceptibility; Encephalomyelitis, Autoimmune, Experimental - drug therapy; Encephalomyelitis, Autoimmune, Experimental - pathology; Encephalomyelitis, Autoimmune, Experimental - prevention & control; experimental autoimmune encephalomyelitis; Female; immunosuppression; Immunosuppressive Agents - pharmacology; Macrophages - metabolism; Macrophages - pathology; Microglia - metabolism; Microglia - pathology; multiple sclerosis; Neuroprotective Agents - pharmacology; Rats; Rats, Inbred Strains; ribavirin; Ribavirin - pharmacology; spinal cord; Spinal Cord - pathology
• ISSN: 0360-4012; 1097-4547
• DOI: 10.1002/jnr.10552

The effect of ribavirin on development of experimental autoimmune encephalomyelitis (EAE) was investigated. The disease was induced in genetically susceptible Dark Agouti rats with syngeneic spinal cord homogenate in complete Freund's adjuvant (SCH‐CFA). Depending on the amount of mycobacteria in CFA, the animals developed either moderate or severe EAE. Ribavirin (1‐β‐D‐ribofuranosyl‐1,2,4‐triazole‐3‐carboxamide) was applied i.p. at a daily dosage of 30 mg/kg in two treatment protocols: from the start of immunization (preventive treatment) or from the onset of the first EAE signs after the induction (therapeutic treatment). Signs of EAE began between 7 and 9 days after induction and peaked at days 11–13. In moderate EAE (mean maximal severity score 3.33 ± 0.21), the recovery was completed by days 23–26, whereas, in severe EAE (mean maximal severity score 4.5 ± 0.23), obvious recovery was not detected. Preventive ribavirin treatment significantly decreased clinical signs after both moderate (score 1.75 ± 0.25, P < 0.05) and severe (score 3.62 ± 0.31, P < 0.015) immunization. Also, disease manifestations were reduced by therapeutic treatment of ribavirin (mean maximal severity score 2.5 ± 0.2 vs. 3.33 ± 0.21 in controls, P < 0.005) but less so in comparison with preventive treatment. Analysis of the effects of ribavirin on histopathologic changes in the spinal cord tissue revealed a reduction of mononuclear cell infiltrates, composed of T cells and macrophages/microglia, and the absence of demyelination, which were pronounced in control EAE animals. Beneficial effects of preventive and therapeutic treatment with ribavirin on development of EAE suggest this nucleoside analogue as a useful candidate for therapy in multiple sclerosis. © 2003 Wiley‐Liss, Inc.